CRISPR Screen Maps the Hidden Control Network of the Body’s Pollution-Sensing Receptor

Deep inside nearly every human cell sits a molecular sentinel that spends its life sniffing the chemical environment. Known as the aryl hydrocarbon receptor, or AHR, this protein acts as a sensor for an astonishing range of molecules: pollutants such as dioxins, dietary compounds from cruciferous vegetables, drugs metabolized by the liver, and, perhaps most remarkably, metabolites produced by the trillions of microbes that inhabit the human gut. When AHR binds one of these chemicals, it travels to the nucleus and switches on a genetic program that governs everything from the integrity of the intestinal barrier to the detoxification of foreign compounds. Decades of research have established that when this signaling pathway goes awry, the consequences can be severe, contributing to metabolic disease, autoimmune disorders, and chronic inflammation. Yet for all its importance, scientists have never had a complete map of the machinery inside human cells that controls when, where, and how strongly AHR fires.

That gap has now been substantially closed. A team of researchers led by Marco Jost of Harvard Medical School, working alongside colleagues including Seth Rakoff-Nahoum, Emily Balskus of Harvard University and the Howard Hughes Medical Institute, and Michael Fischbach of Stanford University, has deployed genome-scale CRISPR screening to systematically identify the regulators of AHR signaling in a human hepatocyte model. The study, published in Genome Biology, represents one of the most comprehensive efforts to date to chart the wiring diagram of this enigmatic receptor. Rather than examining candidate genes one at a time, the team perturbed virtually every gene in the human genome and measured the consequences for AHR activity, allowing the data to reveal the regulatory architecture on an unbiased, genome-wide scale.

The technical approach at the heart of the study is CRISPR interference, or CRISPRi, a refined application of the gene-editing technology that does not cut DNA. Instead, a catalytically dead form of the Cas9 protein is guided to specific genes, where it acts as a reversible brake on transcription, silencing expression without altering the underlying genetic code. By delivering a genome-wide library of guide RNAs into cells engineered so that AHR activation produces a measurable fluorescent or luminescent readout, the researchers could simultaneously test the effect of losing each of roughly twenty thousand human genes on the signaling pathway. Genes whose silencing boosted the readout are candidate negative regulators of AHR; those whose silencing dampened the signal are candidate positive regulators. The beauty of the method lies in its parallelism: thousands of regulatory hypotheses are tested in a single experiment, and the strength of each guide RNA’s enrichment or depletion across the population quantifies the effect.

The results provided immediate validation that the screens had captured genuine biology. Among the hits recovered were the core components of the canonical AHR pathway itself, including the receptor, its nuclear translocator partner ARNT, and factors involved in ligand binding and receptor degradation. This internal consistency mattered, because a screen that failed to rediscover the known players could not be trusted to reveal unknown ones. But beyond the expected genes, the datasets surfaced a large and previously unmapped network of regulators, many of which had never been connected to AHR biology. The breadth of the hit list carried its own message: AHR signaling is not an isolated detoxification circuit but a process deeply interwoven with the general machinery of human cells, touching protein synthesis, trafficking, degradation, and chromatin regulation.

One of the study’s most striking findings concerns the fate of the receptor protein itself. The team identified the E3 ubiquitin ligase UBR5 as a factor that sustains AHR signaling by counteracting the degradation of ligand-bound AHR. Ubiquitin ligases are the enzymes that tag proteins with ubiquitin marks, often condemning them to destruction by the proteasome, and the interplay between AHR and the ubiquitin-proteasome system has long been known to shape receptor levels. What the new work adds is a specific, experimentally validated node within that system: when UBR5 function was compromised, ligand-activated AHR was degraded more readily, and the downstream transcriptional program weakened. In other words, UBR5 acts as a guardian of the activated receptor, extending the window during which AHR can drive gene expression after it encounters its chemical triggers.

The screens also probed how regulation depends on context, a question of particular importance for a receptor that responds to chemically diverse ligands ranging from environmental toxins to microbially derived metabolites such as urolithins, the gut bacterial products that the team included in their chemical analyses. By repeating CRISPRi screens with different inducing molecules, the researchers could classify regulators into those that act generally across all ligands and those whose effects are specific to particular inducers. This distinction is more than a technical curiosity. General regulators represent the pathway’s universal infrastructure, while ligand-specific and cell-type-specific regulators offer potential points of selective manipulation. A drug aimed at a general node would shift AHR activity everywhere; one aimed at a context-specific node could, in principle, tune the receptor’s response to microbial metabolites in the gut without disturbing its detoxification duties in the liver.

That therapeutic logic runs throughout the study’s conclusions. Because AHR sits at the interface of environment, diet, microbiome, and immunity, pharmaceutical interest in the receptor has grown steadily, with attempts to modulate it for inflammatory bowel disease, autoimmune conditions, and metabolic disorders. The obstacle has always been specificity: blunt activation or inhibition of AHR produces widespread effects, some beneficial and some harmful. By identifying cell-type-specific and ligand-specific regulatory components, the new map provides a catalog of candidate targets for more surgical interventions. The authors frame these context-dependent nodes as potential handles for manipulating AHR signaling in a targeted manner for therapeutic benefit, a framing that turns a basic-science dataset into a starting point for drug discovery.

The study also carries implications for understanding host-microbe interactions, one of the most active frontiers in biology. Gut bacteria generate a pharmacopeia of small molecules, and AHR is one of the principal receptors through which these metabolites communicate with the host immune system. Microbial ligands of AHR have been implicated in maintaining the intestinal barrier, calibrating immune responses, and protecting against colitis. A complete regulatory map of the pathway in human cells gives researchers a systematic way to ask how host genetics shapes sensitivity to microbial chemistry, and why individuals or disease states might differ in their responses to the same bacterial metabolites. The integration of chemical screening with genetic screening in this work, including the use of a urolithin library prepared specifically for the study, exemplifies the kind of combined approach that the field of host-microbe chemical biology increasingly demands.

Methodologically, the work demonstrates how far functional genomics has come in dissecting signaling pathways that were once studied gene by gene over decades. The researchers supplemented their primary genome-wide screens with focused sublibrary screens, individual validation assays using independently designed guide RNAs, transcriptional measurements, and biochemical analyses of receptor protein turnover, including western blot experiments documented with full-length unprocessed scans. The classification of hits by activation phenotype across multiple inducers, and the assessment of regulator activity across different cell types, turned a flat list of genes into a structured network with layers of general, ligand-specific, and cell-type-specific control. The datasets, released openly with the article, include raw and analyzed screen data, guide RNA sequences, and primer sequences, providing a resource that other laboratories can mine and reanalyze.

What emerges from the study is a picture of AHR as a receptor embedded in a dense web of cellular governance, its activity shaped not only by which ligand is present but by an extensive cast of proteins controlling its expression, abundance, localization, and longevity. The identification of UBR5 as a protector of the activated receptor offers a mechanistic vignette of how that governance works at the level of protein stability, while the broader network suggests that perturbations far removed from the canonical pathway could nonetheless modulate how human cells respond to the chemical world. For a receptor whose dysfunction has been tied to metabolic and inflammatory disease, and whose normal function depends on a constant dialogue between the body and its microbial inhabitants, the new regulatory map is both a reference atlas and a hypothesis engine. It transforms AHR from a well-studied but incompletely understood sensor into a system whose vulnerabilities and control points can, for the first time, be surveyed in their entirety.

Subject of Research: Genome-scale CRISPR identification of regulators of aryl hydrocarbon receptor signaling in human cells

Article Title: Identification of regulators of aryl hydrocarbon receptor signaling in human cells by genome-scale CRISPR screening

Article References: Verma, M., Adamthwaite, M. L., Desai, K., Ding, Y., Wang, X., Bae, M., Rakoff-Nahoum, S., Balskus, E. P., Fischbach, M. A., & Jost, M. (2026). Identification of regulators of aryl hydrocarbon receptor signaling in human cells by genome-scale CRISPR screening. Genome Biology. https://doi.org/10.1186/s13059-026-04299-1

Image Credits: AI Generated

DOI: 10.1186/s13059-026-04299-1

Keywords: aryl hydrocarbon receptor, CRISPR screening, gene regulation, transcription factor, UBR5, E3 ubiquitin ligase, gut microbiome, microbial metabolites, xenobiotic detoxification, host-microbe interactions, inflammatory disease, hepatocytes